NO324426B1 - 2-aminokarbonyl-9H-purinderivater, samt anvendelse og fremgangsmate for fremstilling derav, og farmasoytisk sammensetning - Google Patents

2-aminokarbonyl-9H-purinderivater, samt anvendelse og fremgangsmate for fremstilling derav, og farmasoytisk sammensetning Download PDF

Info

Publication number: NO324426B1
Authority: NO; Norway
Prior art keywords: formula; compound according; alkyl; compound; optionally substituted
Prior art date: 2000-06-06

Application number

NO20025821A

Other languages

English (en)

Norwegian (no)

Other versions

NO20025821L (no

NO20025821D0 (no

Inventor

Simon John Mantell

Peter Thomas Stephenson

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-06

Filing date

2002-12-04

Publication date

2007-10-08

2000-06-06 Priority claimed from GB0014048A external-priority patent/GB0014048D0/en

2000-10-11 Priority claimed from GB0024920A external-priority patent/GB0024920D0/en

2002-12-04 Application filed by Pfizer filed Critical Pfizer

2002-12-04 Publication of NO20025821D0 publication Critical patent/NO20025821D0/no

2003-02-04 Publication of NO20025821L publication Critical patent/NO20025821L/no

2007-10-08 Publication of NO324426B1 publication Critical patent/NO324426B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Gynecology & Obstetrics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Psychiatry (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Communicable Diseases (AREA)

NO20025821A 2000-06-06 2002-12-04 2-aminokarbonyl-9H-purinderivater, samt anvendelse og fremgangsmate for fremstilling derav, og farmasoytisk sammensetning NO324426B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0014048A GB0014048D0 (en)	2000-06-06	2000-06-06	Purine derivatives
GB0018246A GB0018246D0 (en)	2000-06-06	2000-07-25	Purine derivatives
GB0024920A GB0024920D0 (en)	2000-06-06	2000-10-11	Purine derivatives
PCT/IB2001/000973 WO2001094368A1 (en)	2000-06-06	2001-06-05	2-aminocarbonyl-9h-purine derivatives

Publications (3)

Publication Number	Publication Date
NO20025821D0 NO20025821D0 (no)	2002-12-04
NO20025821L NO20025821L (no)	2003-02-04
NO324426B1 true NO324426B1 (no)	2007-10-08

Family

ID=27255754

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20025821A NO324426B1 (no)	2000-06-06	2002-12-04	2-aminokarbonyl-9H-purinderivater, samt anvendelse og fremgangsmate for fremstilling derav, og farmasoytisk sammensetning

Country Status (33)

Country	Link
EP (1)	EP1292604B1 (es)
JP (2)	JP4129176B2 (es)
KR (1)	KR100484704B1 (es)
CN (1)	CN1249074C (es)
AR (1)	AR030289A1 (es)
AT (1)	ATE431356T1 (es)
AU (2)	AU2001260537B2 (es)
BG (1)	BG107216A (es)
BR (1)	BR0111263A (es)
CA (1)	CA2414018C (es)
CU (1)	CU23240B7 (es)
CZ (1)	CZ20023875A3 (es)
DE (1)	DE60138702D1 (es)
DK (1)	DK1292604T3 (es)
DZ (1)	DZ3439A1 (es)
EA (1)	EA004983B1 (es)
EE (1)	EE200200678A (es)
ES (1)	ES2324816T3 (es)
GC (1)	GC0000287A (es)
HR (1)	HRP20020960A2 (es)
HU (1)	HUP0301330A3 (es)
IL (2)	IL152783A0 (es)
IS (1)	IS6599A (es)
MA (1)	MA26910A1 (es)
MX (1)	MXPA02012033A (es)
NO (1)	NO324426B1 (es)
NZ (1)	NZ522184A (es)
OA (1)	OA12279A (es)
PA (1)	PA8518801A1 (es)
PL (1)	PL360435A1 (es)
SK (1)	SK16752002A3 (es)
TW (1)	TWI227240B (es)
WO (1)	WO2001094368A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7378400B2 (en)	1999-02-01	2008-05-27	University Of Virginia Patent Foundation	Method to reduce an inflammatory response from arthritis
TWI227240B (en) *	2000-06-06	2005-02-01	Pfizer	2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en)	2000-06-27	2005-07-26	Pfizer Inc	Purine derivatives
US20030013675A1 (en) *	2001-05-25	2003-01-16	Boehringer Ingelheim Pharma Kg	Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
NZ532062A (en)	2001-10-01	2006-09-29	Univ Virginia	2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
GB0129273D0 (en)	2001-12-06	2002-01-23	Pfizer Ltd	Crystalline drug form
GB0129270D0 (en) *	2001-12-06	2002-01-23	Pfizer Ltd	Pharmaceutical combination
US6974803B2 (en)	2001-12-06	2005-12-13	Pfizer Inc	Pharmaceutical combination
DE60318192T2 (de) *	2002-04-10	2008-04-30	The University Of Virginia Patent Foundation	Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
US20060178403A1 (en) *	2003-03-07	2006-08-10	Neurocrine Biosciences, Inc.	Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
US7067509B2 (en)	2003-03-07	2006-06-27	Neurocrine Biosciences, Inc.	Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
AR044519A1 (es)	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US7749981B2 (en)	2003-10-21	2010-07-06	Inspire Pharmaceuticals, Inc.	Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7335648B2 (en)	2003-10-21	2008-02-26	Inspire Pharmaceuticals, Inc.	Non-nucleotide composition and method for inhibiting platelet aggregation
JP2007509180A (ja)	2003-10-21	2007-04-12	インスパイアーファーマシューティカルズ，インコーポレイティド	疼痛を治療するための、非ヌクレオチド組成物および方法
WO2005040174A1 (en)	2003-10-21	2005-05-06	Inspire Pharmaceuticals, Inc.	Tetrahydro-furo`3,4-d!dioxole compounds and compositions and method for inhibiting platelet aggregation
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
WO2006028618A1 (en)	2004-08-02	2006-03-16	University Of Virginia Patent Foundation	2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006023272A1 (en)	2004-08-02	2006-03-02	University Of Virginia Patent Foundation	2-polycyclic propynyl adenosine analogs having a2a agonist activity
SG155182A1 (en)	2004-08-02	2009-09-30	Univ Virginia	2-propynyl adenosine analogs with modified 5æ-ribose groups having a2a agonist activity
GT200500281A (es)	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
US7932376B2 (en)	2005-05-05	2011-04-26	Inspire Pharmaceuticals, Inc.	Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
MY144906A (en)	2005-10-21	2011-11-30	Novartis Ag	Human antibodies against il13 and therapeutic uses
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
RU2457209C2 (ru)	2006-04-21	2012-07-27	Новартис Аг	Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а
MX2009003185A (es)	2006-09-29	2009-04-03	Novartis Ag	Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
AU2007315234A1 (en)	2006-10-30	2008-05-08	Novartis Ag	Heterocyclic compounds as antiinflammatory agents
CN101910153B (zh)	2008-01-11	2014-01-22	诺华股份有限公司	作为激酶抑制剂的嘧啶类
ES2676289T3 (es)	2008-06-19	2018-07-18	Takeda Pharmaceutical Company Limited	Compuesto heterocíclico y su uso
PT2391366E (pt)	2009-01-29	2013-02-05	Novartis Ag	Benzimidazoles substituídos para o tratamento de astrocitomas
CN102448978A (zh)	2009-05-29	2012-05-09	辉瑞有限公司	新颖的糖皮质激素受体激动剂
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt)	2009-08-12	2016-05-17	Novartis Ag	compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
PE20121148A1 (es)	2009-08-17	2012-09-07	Intellikine Llc	Compuestos heterociclicos y usos de los mismos
BR112012008061A2 (pt)	2009-08-20	2016-03-01	Novartis Ag	compostos de oxima heterocíclica
UY33597A (es)	2010-09-09	2012-04-30	Irm Llc	Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
EP2673277A1 (en)	2011-02-10	2013-12-18	Novartis AG	[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja)	2011-02-23	2015-11-10	インテリカイン，エルエルシー	複素環化合物およびその使用
BR112013021638A2 (pt)	2011-02-25	2016-08-02	Irm Llc	"compostos inibidores de trk, seu uso e composições que os compreendem"
EP2755976B1 (en)	2011-09-15	2018-07-18	Novartis AG	6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
US20130209543A1 (en)	2011-11-23	2013-08-15	Intellikine Llc	Enhanced treatment regimens using mtor inhibitors
JP2015512425A (ja)	2012-04-03	2015-04-27	ノバルティスアーゲー	チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
WO2014151147A1 (en)	2013-03-15	2014-09-25	Intellikine, Llc	Combination of kinase inhibitors and uses thereof
WO2015084804A1 (en)	2013-12-03	2015-06-11	Novartis Ag	Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en)	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
AU2015294889B2 (en)	2014-07-31	2018-03-15	Novartis Ag	Combination therapy
US12324807B2 (en)	2018-06-01	2025-06-10	Cornell University	Combination therapy for PI3K-associated disease or disorder
TW202140550A (zh)	2020-01-29	2021-11-01	瑞士商諾華公司	使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU5879299A (en) *	1998-10-16	2000-05-08	Monaghan, Sandra Marina	Adenine derivatives
GB9913932D0 (en) *	1999-06-15	1999-08-18	Pfizer Ltd	Purine derivatives
TWI227240B (en) *	2000-06-06	2005-02-01	Pfizer	2-aminocarbonyl-9H-purine derivatives

2001
- 2001-05-31 TW TW090113146A patent/TWI227240B/zh not_active IP Right Cessation
- 2001-06-04 AR ARP010102656A patent/AR030289A1/es active IP Right Grant
- 2001-06-05 WO PCT/IB2001/000973 patent/WO2001094368A1/en not_active Ceased
- 2001-06-05 NZ NZ522184A patent/NZ522184A/en unknown
- 2001-06-05 DK DK01934242T patent/DK1292604T3/da active
- 2001-06-05 OA OA1200200363A patent/OA12279A/en unknown
- 2001-06-05 ES ES01934242T patent/ES2324816T3/es not_active Expired - Lifetime
- 2001-06-05 EP EP01934242A patent/EP1292604B1/en not_active Expired - Lifetime
- 2001-06-05 GC GCP20011415 patent/GC0000287A/en active
- 2001-06-05 MX MXPA02012033A patent/MXPA02012033A/es active IP Right Grant
- 2001-06-05 HR HR20020960A patent/HRP20020960A2/hr not_active Application Discontinuation
- 2001-06-05 EE EEP200200678A patent/EE200200678A/xx unknown
- 2001-06-05 AU AU2001260537A patent/AU2001260537B2/en not_active Ceased
- 2001-06-05 EA EA200201179A patent/EA004983B1/ru not_active IP Right Cessation
- 2001-06-05 CZ CZ20023875A patent/CZ20023875A3/cs unknown
- 2001-06-05 HU HU0301330A patent/HUP0301330A3/hu unknown
- 2001-06-05 CA CA002414018A patent/CA2414018C/en not_active Expired - Fee Related
- 2001-06-05 IL IL15278301A patent/IL152783A0/xx active IP Right Grant
- 2001-06-05 AT AT01934242T patent/ATE431356T1/de not_active IP Right Cessation
- 2001-06-05 DE DE60138702T patent/DE60138702D1/de not_active Expired - Lifetime
- 2001-06-05 PL PL36043501A patent/PL360435A1/xx not_active Application Discontinuation
- 2001-06-05 CN CNB018108024A patent/CN1249074C/zh not_active Expired - Fee Related
- 2001-06-05 SK SK1675-2002A patent/SK16752002A3/sk unknown
- 2001-06-05 JP JP2002501916A patent/JP4129176B2/ja not_active Expired - Fee Related
- 2001-06-05 DZ DZ013439A patent/DZ3439A1/fr active
- 2001-06-05 AU AU6053701A patent/AU6053701A/xx active Pending
- 2001-06-05 KR KR10-2002-7016606A patent/KR100484704B1/ko not_active Expired - Fee Related
- 2001-06-05 BR BR0111263-5A patent/BR0111263A/pt not_active IP Right Cessation
- 2001-06-06 PA PA20018518801A patent/PA8518801A1/es unknown
2002
- 2002-10-23 BG BG107216A patent/BG107216A/bg unknown
- 2002-10-29 IS IS6599A patent/IS6599A/is unknown
- 2002-11-26 CU CU20020281A patent/CU23240B7/es not_active IP Right Cessation
- 2002-12-02 MA MA26930A patent/MA26910A1/fr unknown
- 2002-12-04 NO NO20025821A patent/NO324426B1/no not_active IP Right Cessation
2007
- 2007-06-21 IL IL184144A patent/IL184144A/en not_active IP Right Cessation
2008
- 2008-01-15 JP JP2008005804A patent/JP2008150383A/ja active Pending

Also Published As

Publication number	Publication date
NO20025821L (no)	2003-02-04
MA26910A1 (fr)	2004-12-20
GC0000287A (en)	2006-11-01
CA2414018C (en)	2007-10-16
EA200201179A1 (ru)	2003-04-24
CN1434830A (zh)	2003-08-06
EE200200678A (et)	2004-06-15
ES2324816T3 (es)	2009-08-17
ATE431356T1 (de)	2009-05-15
OA12279A (en)	2003-01-01
BR0111263A (pt)	2003-06-17
DZ3439A1 (fr)	2001-12-13
CZ20023875A3 (cs)	2004-02-18
CU23240B7 (es)	2007-10-17
WO2001094368A1 (en)	2001-12-13
HRP20020960A2 (en)	2005-02-28
PL360435A1 (en)	2004-09-06
HUP0301330A2 (hu)	2003-08-28
EP1292604B1 (en)	2009-05-13
IL152783A0 (en)	2003-06-24
CN1249074C (zh)	2006-04-05
SK16752002A3 (sk)	2004-05-04
JP2008150383A (ja)	2008-07-03
AR030289A1 (es)	2003-08-20
JP4129176B2 (ja)	2008-08-06
NO20025821D0 (no)	2002-12-04
IL184144A (en)	2008-11-26
TWI227240B (en)	2005-02-01
NZ522184A (en)	2004-05-28
HUP0301330A3 (en)	2005-02-28
IS6599A (is)	2002-10-29
KR20030032962A (ko)	2003-04-26
DK1292604T3 (da)	2009-06-15
EA004983B1 (ru)	2004-10-28
DE60138702D1 (de)	2009-06-25
MXPA02012033A (es)	2003-04-25
EP1292604A1 (en)	2003-03-19
BG107216A (bg)	2003-05-30
CA2414018A1 (en)	2001-12-13
PA8518801A1 (es)	2002-09-17
IL184144A0 (en)	2007-10-31
AU6053701A (en)	2001-12-17
HK1089447A1 (zh)	2006-12-01
AU2001260537B2 (en)	2006-05-25
HK1054042A1 (en)	2003-11-14
KR100484704B1 (ko)	2005-04-22
JP2003535871A (ja)	2003-12-02

Publication	Publication Date	Title
NO324426B1 (no)	2007-10-08	2-aminokarbonyl-9H-purinderivater, samt anvendelse og fremgangsmate for fremstilling derav, og farmasoytisk sammensetning
DE60119492T2 (de)	2006-11-09	Purinderivate
AU2001260537A1 (en)	2002-03-07	2-aminocarbonyl-9H-purine derivatives
AU764106B2 (en)	2003-08-07	Purine derivatives
US6753322B2 (en)	2004-06-22	2-aminocarbonyl-9H-purine derivatives
AU768308B2 (en)	2003-12-04	Purine derivatives
US6448236B1 (en)	2002-09-10	Purine derivatives
KR20030036248A (ko)	2003-05-09	푸린 유도체
IL152783A (en)	2008-11-26	2-aminocarbonyl-9h-purine derivatives
HK1089447B (en)	2008-08-22	A process for the preparation of 2-aminocarbonyl-9h-purine derivatives and the intermediates thereof

Legal Events

Date	Code	Title	Description
2012-01-23	MM1K	Lapsed by not paying the annual fees